OneChain' stakeholders
We count with the support of cutting-edge organizations from the private and public sector
Founder
Dr. Menéndez, is world renowned for his work in the field of childhood leukaemia. Directs the Josep Carreras Institute's stem cell biology, leukaemia development and immunotherapy group. More than 180 of his studies have been published by the world's most prestigious scientific journals. Awarded by the triennial ED Thomas Postdoctoral Fellowship, by the Josep Carreras Foundation, and three times by the European Research Council (ERC), the most important scientific funding organisation in Europe.
Investors
Institutions
Spin-off from Josep Carreras Foundation. The projects have been supported by the following institutions
y por la Unión Europea NextGenerationEU / PRTR
OneChain Immunotherapeutics S.L. ha sido beneficiaria de un proyecto subvencionado por el CDTI con la colaboración del Ministerio de Ciencia e Innovación y Cofinanciado por la Unión Europea- Next Generation EU
Número de expediente SNEO-20211018 - PLAN DE EMPRESA ONECHAIN IMMUNOTHERAPEUTICS S.L. (01/01/2022-31/12/2022 - 325.000€)
El objetivo general del plan es desarrolar un nuevo método eficaz para la generación selectiva a gran escala de células T citotóxicas (células T Vd1+, también conocidas como DOTs) a partir de sangre de cordón umbilical humano, óptimo para la aplicación clínica en la inmunoterapia adoptiva del cáncer: es decir, el desarrollo de una nueva plataforma de terapia CAR-T de origen alogénico.
Project funded by the European Union’s EIC Transition programme under Grant Agreement nº 101113067.